Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Last year (2025), Novo Nordisk had sought to further position itself in the obesity drug market with a bid to acquire Metsera, a New York-based clinical-stage bio/pharmaceutical company focused on obesity and cardiometabolic diseases, eventually losing a bidding war with Pfizer, which acquired Metsera last November (November 2025) in a deal worth up to $11 billion
"Medicare Advantage Insurers Made Nearly 50 Million Prior Authorization Determinations in 2023." kff.org Truveta
249, 74 (2022), Abstract Ferredoxin:NADP(H) Oxidoreductase Abundance and Location Influences Redox Poise and Stress Tolerance: M
Given the high prevalence of fatty liver in diabetic patients (estimated at 5570%), initiating or switching to a GLP-1 agonist addresses both conditions simultaneously
